Literature DB >> 17242878

Acute tumor lysis syndrome caused by transcatheter oily chemoembolization in a patient with a large hepatocellular carcinoma.

Noriaki Sakamoto1, Shuichi Monzawa, Hidenobu Nagano, Hogara Nishizaki, Yasuaki Arai, Kazuro Sugimura.   

Abstract

Acute tumor lysis syndrome results from a sudden and rapid release of products of cellular breakdown after anticancer therapy. Severe alterations of metabolic profile might occur and result in acute renal failure. We present a patient with a large hepatocellular carcinoma who received transcatheter oily chemoembolization and died subsequently of this syndrome. To our knowledge, there has been only one report of this syndrome induced by chemoembolization for hepatocellular carcinoma. This case illustrates the need to anticipate the development of acute tumor lysis syndrome when chemoembolization is planned for a large hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17242878     DOI: 10.1007/s00270-005-0240-8

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  12 in total

1.  Tumour Lysis Syndrome: a Rare Complication of Trans-Arterial Chemo-Embolisation with Doxorubicin Beads for Hepatocellular Carcinoma.

Authors:  Diana Katiman; Jeeta Manikam; Khean-Lee Goh; Basri Johan Abdullah; Sanjiv Mahadeva
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 2.  Medical management of tumor lysis syndrome, postprocedural pain, and venous thromboembolism following interventional radiology procedures.

Authors:  Ali Faramarzalian; Keith B Armitage; Baljendra Kapoor; Sanjeeva P Kalva
Journal:  Semin Intervent Radiol       Date:  2015-06       Impact factor: 1.513

Review 3.  Tumor lysis syndrome and primary hepatic malignancy: case presentation and review of the literature.

Authors:  Sean P Zivin; Youssef Elias; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2015-03       Impact factor: 1.513

Review 4.  Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review.

Authors:  Pei-Min Hsieh; Kao-Chen Hung; Yaw-Sen Chen
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

5.  An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review.

Authors:  Danica Maria Vodopivec; Jose Enrique Rubio; Alessia Fornoni; Oliver Lenz
Journal:  Case Rep Med       Date:  2012-05-27

6.  Safety and effectiveness of multi-antenna microwave ablation-oriented combined therapy for large hepatocellular carcinoma.

Authors:  Tian-Qi Zhang; Zhi-Mei Huang; Jing-Xian Shen; Gui-Qun Chen; Lu-Jun Shen; Fei Ai; Yang-Kui Gu; Wang Yao; Yan-Yang Zhang; Rong-Ping Guo; Min-Shan Chen; Jin-Hua Huang
Journal:  Therap Adv Gastroenterol       Date:  2019-08-21       Impact factor: 4.409

7.  Balloon-Occluded Trans-Arterial Chemo-Embolization Technique with Repeated Alternate Infusion of Cisplatin Solution and Sparse Gelatin Slurry (RAIB-TACE) for Large Hepatocellular Carcinoma Nodules More than 7 cm in Diameter.

Authors:  Toshiyuki Irie; Nobuyuki Takahashi; Toshiro Kamoshida; Junya Kashimura; Hiroyuki Ariga
Journal:  Biomed Res Int       Date:  2020-01-19       Impact factor: 3.411

8.  Clinical factors associated with dense and wedge-shaped nephrograms detected 24 h after chemoembolization.

Authors:  Wayne L Monsky; Anokh Pahwa; Chin-Shang Li; Richard W Katzberg
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11       Impact factor: 2.740

Review 9.  Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature.

Authors:  Aibek E Mirrakhimov; Alaa M Ali; Maliha Khan; Aram Barbaryan
Journal:  Rare Tumors       Date:  2014-06-13

10.  The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma.

Authors:  Jianfei Tu; Zhongzhi Jia; Xihui Ying; Dengke Zhang; Shaoqin Li; Feng Tian; Guomin Jiang
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.